Corcept Therapeutics Plunges 33% After Loss in Patent Battle With With Teva

Tiger Newspress01-02

Corcept Therapeutics plummeted 32.6% in premarket trading Tuesday after a loss in a patent trial with Teva Pharmaceuticals over a patent for Cushing’s syndrome drug Korlym.

The court found that Corcept (CORT) hadn't met its burden of proving induced infringement, according to a court ruling late Friday by Judge Renée Marie Bumb of the US District Court for the District of New Jersey.

"ORDERED that Teva has not infringed, and that Teva’s making, using, offering to sell, selling, or importing Teva’s generic mifepristone product will not infringe, claims 10–13 of the ʼ214 Patent or claims 1, 6, 7, and 9 of the ’800 Patent," the judge wrote in the opinion on Friday.

The court ruling comes after a trial in late September, which sent Corcept (CORT) shares plunging 17% on Sept. 17.

Corcept (CORT) has been in a patent battle with Teva (TEVA) over a patent for Cushing’s syndrome drug Korlym, marketed by Corcept. In December 2021 Teva lost an attempt to invalidate a parent for Korlym.

Corcept (CORT) originally sued Teva (TEVA) in federal court in March 2018 to prevent it from marketing a generic version of Korlym.

Corcept's (CORT) short interest is 18%.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

Leave a comment
1
1